Is Merck & Co., Inc. (MRK) A Good Stock To Buy Now?

Core Thesis - Merck & Co., Inc. is viewed positively by analysts, with a current share price of $117.11 and trailing and forward P/E ratios of 15.91 and 22.57 respectively [1] Financial Performance - In fiscal year 2025, Merck reported a fourth-quarter revenue of $16.4 billion, reflecting a 6% year-over-year increase, with GAAP EPS of $1.41 and non-GAAP EPS of $1.92, while maintaining gross margins around 77% [2] - For the full year, revenue increased by 8% to $64.2 billion, with GAAP EPS of $5.94 and non-GAAP EPS of $7.82, alongside approximately $23 billion in operating cash flow and about $19 billion in free cash flow [3] Revenue Drivers - Keytruda remains a significant growth driver, generating approximately $30.1 billion in revenue in 2025, up 10% year-over-year, supported by expanded indications and durable pricing power [4] - Vaccines contributed significantly, with Gardasil generating around $9.2 billion in revenue, driven by strong global demand [4] - The Animal Health segment produced roughly $6.0 billion in revenue, providing stable growth and diversification [4] Pipeline and Future Growth - The company is advancing its pipeline, with sotatercept showing promise for pulmonary arterial hypertension and potential multibillion-dollar revenue opportunities [5] - Additional oncology combination therapies and cardiometabolic and immunology assets are progressing towards Phase 3 readouts in 2026-2027, aimed at enhancing long-term growth prospects [5] Capital Allocation and Guidance - Merck maintained disciplined capital allocation, spending approximately $17 billion on R&D while focusing on bolt-on acquisitions and late-stage assets [6] - Management projects 2026 revenue between $63.5 billion and $65.5 billion, with non-GAAP EPS expected to be between $8.20 and $8.45, indicating confidence in near-term growth [6]